Cancer cells remaining undetected in the body following treatment regimens can cause recurrence. Recent studies suggest that this debilitating issue could be a result of heterogeneous characteristics of cancer cells; thus residual cells are likely to be drug resistant and/or not targeted by the initial treatment. Scientists at NCCS believe that identifying the heterogeneity of the cancer cells and providing a targeted therapy specific for different cell fractions can resolve this issue. Continue reading
Available Technology & Capabilities
NCCS Meetings Calendar
Technology Categories
- Cancer Biology (6)
- Cell Biology (2)
- Computational Biology (3)
- Genetics (3)
- Immunology (5)
- Metabolic Diseases (3)
- Microbial Biology (4)
- Neuroscience (1)
- Stem Cells (12)
Products and Services
- Biopharma (18)
- Cell Therapy (6)
- Diagnostics (2)
- In-vitro Platform (8)
- Medical Device (3)
- Nutraceutical (2)
- Regenerative medicine (3)
- Umbilical Cord Blood Banking (3)
-
Related Links